I re-read this one last night, amazing, so this means there is potential for revenue without having to go through a Phase 3 trial? (see below quote from 51 Capital)
Did you guys realise that? How is this possible? Has it got to do with the fact that the DoD and the FDA are working together in this area?
Or is it more to do with the fact that this will be within the military and not the general public thus different rules and pathways can be followed?
I understand there is potential for revenue under the SAS through the TGA in Australia for OA and MPS, but revenue in regards to CHIKV will be quick if the DoD don't need a trial to occur. I agree, the market is completely overlooking this and the benefits and potential of iPPS totally! DOYR.
Potential DoD revenue from PAR maybe as soon as 2020?The next stepis likely to start discussions with the US department of defence (DoD) who could start to purchase iPPS from Paradigm to treat service men and women who are suffering with chikungunya (CHIKV).
Thebest case is the DoD are happy with the results and safety and order anywherefrom $1m - $5m worth of product to begin treatments. Worst case, they want to run another trial inCHIKV and will either fund or co-fund this trial (which is not a badoutcome). There are thousands of service men and women with CHIKV and nocurrent treatment. Our estimates are a course of treatment would cost between$3000 - $5000 per treatment ($3-$5m per 1000 people).We rank the probability of purchasing before a trial at 50/50 odds – Given the strong safety profile and lack of alternative treatments there is a good chance they move forward with purchases. This is something the market seems to be completely overlooking.1
Reference:
(1) http://www.fiftyonecapital.com/monthly-updates-1/2019/6/11/may-2019
- Forums
- ASX - By Stock
- Fiftyone Capital Update
I re-read this one last night, amazing, so this means there is...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.95M |
Open | High | Low | Value | Volume |
22.5¢ | 23.5¢ | 22.0¢ | $65.40K | 290.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 96390 | 22.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 138166 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 91390 | 0.220 |
6 | 88958 | 0.215 |
5 | 131050 | 0.210 |
4 | 104982 | 0.205 |
6 | 184175 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 138166 | 5 |
0.240 | 40833 | 1 |
0.250 | 15000 | 1 |
0.255 | 9785 | 1 |
0.260 | 26050 | 3 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online